Target Name: CYTH1
NCBI ID: G9267
Review Report on CYTH1 Target / Biomarker Content of Review Report on CYTH1 Target / Biomarker
CYTH1
Other Name(s): FLJ41900 | SEC7 | CYH1_HUMAN | CYTOHESIN-1 | PH, SEC7 and coiled-coil domain-containing protein 1 | Cytohesin-1 | B2-1 | Cytohesin 1, transcript variant 1 | pleckstrin homology, Sec7 and coiled-coil domains 1 | CYTH1 variant 1 | Cytohesin-1 (isoform 1) | Pleckstrin homology, Sec7 and coiled-coil domains 1 | Cytoadhesin 1 | PSCD1 | D17S811E | cytohesin 1 | Homolog of secretory protein SEC7 | homolog of secretory protein SEC7 | FLJ34050 | Cytohesin 1 | cytoadhesin 1 | SEC7 homolog B2-1

CYTH1: A Potential Drug Target for Various Diseases

CYTH1 (FLJ41900) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and kidneys. It is a member of the cytoskeleton family and is involved in the formation and maintenance of the endoplasmic reticulum, which is the network of vesicles that transports proteins from the ER to other parts of the cell.

CYTH1 is also known as calbindin, a protein that is often used as a biomarker for various diseases, including cancer, Alzheimer's disease, and Parkinson's disease. Its levels are often elevated in these diseases, and it has been shown to be involved in the progression of these conditions.

One of the unique features of CYTH1 is its ability to interact with other proteins, particularly those that are involved in the formation and maintenance of the endoplasmic reticulum. This interaction suggests that CYTH1 may play a role in the regulation of protein synthesis and may be a potential drug target.

In addition to its role in the endoplasmic reticulum, CYTH1 is also involved in the regulation of cell signaling pathways that are important for various cellular processes, including cell growth, differentiation, and inflammation. This suggests that it may be a useful target for drugs that are aimed at modulating these pathways.

CYTH1 is also expressed in various tissues throughout the body and has been shown to be involved in the development and maintenance of various diseases, including cancer, Alzheimer's disease, and Parkinson's disease. Its levels are often elevated in these conditions, and it has been shown to be involved in the progression of these conditions.

One of the unique features of CYTH1 is its ability to interact with other proteins, particularly those that are involved in the formation and maintenance of the endoplasmic reticulum. This interaction suggests that CYTH1 may play a role in the regulation of protein synthesis and may be a potential drug target.

In addition to its role in the endoplasmic reticulum, CYTH1 is also involved in the regulation of cell signaling pathways that are important for various cellular processes, including cell growth, differentiation, and inflammation. This suggests that it may be a useful target for drugs that are aimed at modulating these pathways.

Overall, CYTH1 is a protein that is expressed in various tissues throughout the body and is involved in the formation and maintenance of the endoplasmic reticulum. Its unique ability to interact with other proteins suggests that it may be a potential drug target and may be worth further investigation. Further research is needed to fully understand the role of CYTH1 in the development and progression of various diseases.

Protein Name: Cytohesin 1

Functions: Promotes guanine-nucleotide exchange on ARF1, ARF5 and ARF6. Promotes the activation of ARF factors through replacement of GDP with GTP. Plays an important role in membrane trafficking, during junctional remodeling and epithelial polarization, through regulation of ARF6 activity

The "CYTH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYTH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CYTH2 | CYTH3 | CYTH4 | CYTIP | CYTL1 | Cytochrome b5 reductase | Cytochrome bc1 complex | Cytochrome c oxidase | Cytochrome P450 1A (CYP1A) | Cytochrome P450 26 | Cytochrome P450 3A (CYP3A) | Cytochrome P450 4A | Cytochrome P450 Enzymes | Cytohesin | Cytoplasmatic dynein | Cytoplasmic dynein complex | CYTOR | CYYR1 | CYYR1-AS1 | CZIB | D21S2088E | D2HGDH | DAAM1 | DAAM2 | DAAM2-AS1 | DAB1 | DAB1-AS1 | DAB2 | DAB2IP | DACH1 | DACH2 | DACT1 | DACT2 | DACT3 | DACT3-AS1 | DAD1 | DAG1 | DAGLA | DAGLB | DALRD3 | DANCR | DAND5 | DANT2 | DAO | DAOA | DAOA-AS1 | DAP | DAP3 | DAPK1 | DAPK1-IT1 | DAPK2 | DAPK3 | DAPL1 | DAPP1 | DARS1 | DARS1-AS1 | DARS2 | DAW1 | DAXX | DAZ1 | DAZ2 | DAZ3 | DAZ4 | DAZAP1 | DAZAP2 | DAZAP2P1 | DAZL | DBET | DBF4 | DBF4B | DBF4P1 | DBH | DBH-AS1 | DBI | DBIL5P | DBIL5P2 | DBIP2 | DBIRD complex | DBN1 | DBNDD1 | DBNDD2 | DBNL | DBP | DBR1 | DBT | DBX1 | DBX2 | DCAF1 | DCAF10 | DCAF11 | DCAF12 | DCAF12L1 | DCAF12L2 | DCAF13 | DCAF13P3 | DCAF15 | DCAF16 | DCAF17 | DCAF4 | DCAF4L1